Unlock Updated Guidelines For The Treatment Of Rrmm

Unlock Updated Guidelines for the Treatment of RRMM

Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM

Multiple Myeloma Hub

What are the latest updates to the NCCN guidelines for the management of MM?

Multiple Myeloma Hub

Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results

International Myeloma Foundation

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-Farber

Dana-Farber Cancer Institute

What is HRSMM? What are the guidelines?

HealthTree University for Multiple Myeloma

What Are the Treatment Options for Relapsed/Refractory Myeloma?

Patient Empowerment Network

New horizons in the treatment of relapsed and refractory myeloma

Treatment Options in RRMM

Targeted Oncology

Treatment Options for Refractory/Relapsed Multiple Myeloma

Personalized Medicine in Multiple Myeloma: The Latest Treatment Advancements

Bristol Myers Squibb

New Directions in Treating Multiple Myeloma in the Era of Novel Agents

Dana-Farber Cancer Institute

New treatment for patients with relapsed/refractory multiple myeloma

Winship Cancer Institute of Emory University

Improving treatment options for patients with R/R myeloma: immunotherapies & CELMoDs

VJHemOnc – Video Journal of Hematology & HemOnc

New horizons in the treatment of relapsed and refractory myeloma

Unlocking the Potential of Resveratrol: Enhancing Treatment for Refractory Multiple Myeloma

Cancer Self-Defense 101

The growing importance of CELMoDs in the treatment of R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM

International Myeloma Foundation

Fixing Disparities in Myeloma: The Key to Unlock Cures for All | MCRT Webcast Feb 27, 2021

HealthTree Foundation for Multiple Myeloma